Disclosure of cinnamic acid/4,9-diaminoacridine conjugates as multi-stage antiplasmodial hits

Bioorg Med Chem. 2024 Apr 15:104:117714. doi: 10.1016/j.bmc.2024.117714. Epub 2024 Apr 3.

Abstract

4,9-diaminoacridines with reported antiplasmodial activity were coupled to different trans-cinnamic acids, delivering a new series of conjugates inspired by the covalent bitherapy concept. The new compounds were more potent than primaquine against hepatic stages of Plasmodium berghei, although this was accompanied by cytotoxic effects on Huh-7 hepatocytes. Relevantly, the conjugates displayed nanomolar activities against blood stage P. falciparum parasites, with no evidence of hemolytic effects below 100 µM. Moreover, the new compounds were at least 25-fold more potent than primaquine against P. falciparum gametocytes. Thus, the new antiplasmodial hits disclosed herein emerge as valuable templates for the development of multi-stage antiplasmodial drug candidates.

Keywords: Antimalarial; Cinnamic acid; Covalent bitherapy; Diaminoacridine; Multi-target.

MeSH terms

  • Antimalarials* / pharmacology
  • Antimalarials* / therapeutic use
  • Cinnamates*
  • Disclosure
  • Humans
  • Malaria, Falciparum* / drug therapy
  • Plasmodium berghei
  • Plasmodium falciparum
  • Primaquine / pharmacology

Substances

  • Antimalarials
  • Primaquine
  • cinnamic acid
  • Cinnamates